6 min read

The Clorox Company (CLX) Cyberattack Lawsuit and Financial Analysis: Impact on Fundamentals and Market Position

by monexa-ai

Comprehensive analysis of The Clorox Company’s $380M cyberattack lawsuit against Cognizant, recent financial results, and implications for investors.

Corporate office workers discussing near computers with a soft purple backdrop

Corporate office workers discussing near computers with a soft purple backdrop

Introduction#

The Clorox Company (CLX faces a pivotal moment following a $380 million lawsuit against its IT service provider, Cognizant, for alleged gross negligence in a cyberattack that compromised its systems. This legal action exposes critical vulnerabilities in third-party vendor cybersecurity protocols and has coincided with notable financial developments, including a recent stock price drop to $127.24, down -2.73% intraday. The timing and scale of this lawsuit are particularly significant given Clorox’s operational and financial metrics as of mid-2024, underscoring urgent strategic and risk management challenges for the consumer staples giant.

Stay ahead of market trends

Get comprehensive market analysis and real-time insights across all sectors.

Explore Market Overview

The Clorox Cyberattack Lawsuit: Key Developments and Implications#

The lawsuit filed by Clorox claims that Cognizant’s failure to properly verify employee identities during password resets directly enabled hackers to infiltrate Clorox’s network through social engineering tactics. This breach reportedly resulted in approximately $49 million in immediate remediation costs and $331 million in indirect damages, including business interruptions and reputational harm (Reuters, New York Times.

Hackers, attributed to the Scattered Spider group, exploited lax authentication protocols in Cognizant’s help desk operations, bypassing technical safeguards through deception and impersonation. This incident highlights the critical importance of multi-factor authentication and rigorous vendor oversight in protecting corporate IT infrastructure.

The operational fallout included system shutdowns and supply chain delays, affecting Clorox’s ability to meet demand and resulting in lost sales. The lawsuit’s $380 million claim is reflective not only of direct costs but also the broader financial and strategic risks posed by cybersecurity breaches in a highly competitive consumer staples market.

Financial Performance Overview: FY 2024 and Historical Context#

Clorox’s financial results for the fiscal year ending June 30, 2024, reveal mixed signals amid the cybersecurity crisis. Revenue declined by -4.01% year-over-year to $7.09 billion, reflecting softness in demand or possible operational disruptions. Gross profit margin improved to 42.97%, up from 39.36% in FY 2023, indicating some success in cost management despite revenue pressures.

Operating income decreased to $916 million from $1.22 billion the prior year, compressing operating margin to 12.91% from 16.57%. Notably, net income more than doubled to $280 million from $149 million, boosted by tax and non-operating factors, yielding a net margin of 3.95%. This divergence suggests operational challenges but some financial engineering or non-recurring gains bolstering bottom-line results.

The company’s research and development expenses remain modest at $126 million (1.74% of revenue), consistent with industry norms in consumer staples, emphasizing focus on incremental innovation rather than disruptive change.

Key Financial Metrics Table#

Metric FY 2024 FY 2023 Change
Revenue $7.09B $7.39B -4.01%
Gross Profit Margin 42.97% 39.36% +3.61pp
Operating Income $916M $1.22B -24.92%
Operating Margin 12.91% 16.57% -3.66pp
Net Income $280M $149M +87.92%
Net Margin 3.95% 2.02% +1.93pp
R&D Expenses $126M (1.74%) $138M (1.87%) -8.70%

Balance Sheet and Cash Flow Insights#

As of June 2024, Clorox maintains a solid asset base of $5.75 billion, with total liabilities at $5.26 billion, leaving a narrow equity base of $328 million. The company's current ratio stands at 0.74x, indicating liquidity constraints relative to short-term obligations. Net debt increased slightly to $2.7 billion, reflecting sustained leverage with a net debt to EBITDA ratio of 1.97x, a moderate leverage level within the sector.

Cash flow from operations contracted to $695 million (-39.98%), with free cash flow down -48.06% to $483 million, pressured by a working capital outflow of $241 million and ongoing capital expenditures of $212 million. Dividends paid totaled $595 million, representing an 86.6% payout ratio, underscoring commitment to shareholder returns despite cash flow pressures.

Cash Flow and Balance Sheet Highlights#

Metric FY 2024 FY 2023 Change
Net Cash from Operations $695M $1.16B -39.98%
Free Cash Flow $483M $930M -48.06%
Capital Expenditures $212M $228M -7.02%
Dividends Paid $595M $583M +2.06%
Total Debt $2.9B $2.92B -0.68%
Current Ratio 0.74x 0.81x -0.07x

Market Reaction and Valuation#

The stock price decline of -2.73% to $127.24 reflects market concerns around the cyberattack’s impact on Clorox’s financial health and operational continuity. The current price-to-earnings ratio of 22.84x remains in line with consumer staples peers, though forward PE estimates indicate modest compression to 18.58x in 2025 as earnings growth stabilizes.

Clorox’s dividend yield of 3.84% is attractive in the sector, supported by a consistent payout history, but the lack of dividend growth over five years signals a cautious capital allocation stance amid evolving risks.

Clorox operates in a mature consumer staples sector characterized by steady demand but increasing pressure from supply chain disruptions and inflationary costs. The cybersecurity breach introduces a new dimension of risk management that competitors are also addressing with enhanced IT governance and vendor oversight.

Innovation in sustainable and health-conscious products is a key sector trend, and Clorox’s R&D investment remains conservative relative to peers, potentially limiting differentiation.

What This Means for Investors: Strategic and Financial Considerations#

Investors should monitor Clorox’s legal proceedings against Cognizant closely, as the $380 million claim could materially affect future cash flows and earnings if not resolved favorably. The operational disruptions documented suggest potential for ongoing supply chain and demand impacts.

Financial metrics reveal resilience in gross margins but pressure on operating efficiency and cash flow generation. The company’s leverage and liquidity ratios warrant attention, particularly given the high dividend payout ratio which could constrain financial flexibility.

Strategically, Clorox must strengthen cybersecurity protocols and vendor management to mitigate reputational and operational risks. The post-breach investments in multi-factor authentication and employee training are positive steps but will require ongoing capital and operational focus.

Historical Context and Management Execution#

Historically, Clorox has demonstrated the ability to manage cost structures effectively during revenue downturns, as seen in the 2023 fiscal year. However, the marked decline in operating income and cash flow in 2024 indicates execution challenges amidst external shocks like the cyberattack.

The management team, led by CEO Linda J. Rendle, faces the test of balancing short-term remediation efforts with long-term strategic initiatives, particularly in innovation and sustainability, to maintain competitive positioning.

Key Takeaways#

  • The $380 million lawsuit against Cognizant highlights significant cybersecurity vulnerabilities with direct financial and operational consequences for Clorox.
  • FY 2024 results show mixed financial performance: revenue down -4.01%, gross margin improvement to 42.97%, but operating income down -24.92%.
  • Net income more than doubled due to non-operational factors, while cash flow and liquidity metrics weakened.
  • Dividend yield remains attractive at 3.84%, but payout ratio at 86.6% suggests limited room for dividend growth.
  • Market reaction reflects uncertainty around breach impact and legal outcomes, with stock down -2.73% intraday.
  • Strategic focus on cybersecurity enhancements and vendor oversight is critical to restoring operational resilience and investor confidence.

For continued insights on The Clorox Company’s financial performance and industry trends, investors may review prior analyses and sector reports linked on the Monexa AI Clorox dashboard.

Abstract AI interface with digital network connections in a futuristic workspace with purple ambient lighting

DocuSign AI Strategy Boosts Growth and Margins Amid Digital Agreement Competition

DocuSign's AI-powered IAM platform drives rapid adoption, margin expansion, and competitive edge against Adobe Sign, reshaping its growth trajectory.

Corporate help desk with computers and digital security icons in a modern office setting

The Clorox Company (CLX) Cybersecurity Lawsuit and Financial Analysis: Implications for Investors

Detailed analysis of The Clorox Company's $380M cybersecurity lawsuit against Cognizant and its impact on financials, market position, and strategic outlook.

Two business professionals review financial data in a modern purple-accented office

Molina Healthcare Inc. (MOH) Faces Crisis Amid Earnings Miss and Securities Fraud Investigations

Molina Healthcare's recent earnings miss, guidance cuts, and securities fraud investigations highlight rising medical costs and regulatory challenges impacting the managed care sector.

Laboratory equipment with digital data overlays in a sleek workspace lit by soft purple hues

Revvity, Inc. Q2 2025 Analysis: Navigating China Diagnostics Challenges and Life Sciences Growth

Explore Revvity's Q2 2025 earnings beat, China diagnostics headwinds, margin pressures, and strategic initiatives shaping its future growth trajectory.

Two business professionals shake hands in a modern office with digital icons floating around them

Gen Digital Inc. Strategic Pivot: AI-Driven Cybersecurity Meets Financial Wellness

Gen Digital integrates AI, cybersecurity, and fintech with MoneyLion acquisition, driving revenue growth and expanding its digital freedom ecosystem.

Laboratory glass vials and syringe on reflective table with blurred scientific equipment in the background

West Pharmaceutical Services (WST) Q2 2025 Earnings Beat, GLP-1 Growth, and Strategic Market Position

West Pharmaceutical Services (WST) reports strong Q2 2025 earnings driven by GLP-1 demand and HVP expansion, raising full-year guidance amid robust financial health.